OP Asset Management Ltd Purchases Shares of 148,929 Myriad Genetics, Inc. $MYGN

Posted by Stanley Muller on Jul 1st, 2026

OP Asset Management Ltd purchased a new position in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 148,929 shares of the company’s stock, valued at approximately $670,000.

A number of other large investors have also recently made changes to their positions in MYGN. Assenagon Asset Management S.A. raised its stake in Myriad Genetics by 23.9% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,446,961 shares of the company’s stock worth $6,511,000 after acquiring an additional 279,227 shares during the last quarter. SG Americas Securities LLC grew its stake in Myriad Genetics by 30.3% during the 1st quarter. SG Americas Securities LLC now owns 51,865 shares of the company’s stock valued at $233,000 after purchasing an additional 12,057 shares during the last quarter. Invesco Ltd. grew its stake in Myriad Genetics by 2.4% during the 4th quarter. Invesco Ltd. now owns 507,180 shares of the company’s stock valued at $3,119,000 after purchasing an additional 12,026 shares during the last quarter. Mercer Global Advisors Inc. ADV increased its holdings in shares of Myriad Genetics by 62.7% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 26,886 shares of the company’s stock valued at $165,000 after purchasing an additional 10,359 shares during the period. Finally, Vestal Point Capital LP increased its holdings in shares of Myriad Genetics by 103.8% in the fourth quarter. Vestal Point Capital LP now owns 1,223,000 shares of the company’s stock valued at $7,521,000 after purchasing an additional 623,000 shares during the period. 99.02% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

MYGN has been the subject of a number of research reports. Wells Fargo & Company decreased their target price on Myriad Genetics from $6.00 to $5.50 and set an “equal weight” rating for the company in a report on Wednesday, May 6th. TD Cowen cut their price target on shares of Myriad Genetics from $7.00 to $6.00 and set a “hold” rating on the stock in a report on Wednesday, May 6th. Finally, Weiss Ratings lowered shares of Myriad Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, June 24th. One analyst has rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Myriad Genetics has an average rating of “Hold” and a consensus price target of $6.50.

View Our Latest Research Report on Myriad Genetics

Insider Buying and Selling

In other news, Director Paul Bisaro bought 7,500 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The stock was purchased at an average cost of $3.69 per share, for a total transaction of $27,675.00. Following the purchase, the director directly owned 97,441 shares in the company, valued at approximately $359,557.29. This trade represents a 8.34% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Rashmi Kumar sold 15,000 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $4.46, for a total transaction of $66,900.00. Following the sale, the director directly owned 171,889 shares in the company, valued at $766,624.94. This trade represents a 8.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.90% of the stock is owned by company insiders.

Myriad Genetics Price Performance

Shares of MYGN opened at $5.71 on Wednesday. The business’s 50-day moving average is $4.46 and its two-hundred day moving average is $5.07. The company has a market capitalization of $539.31 million, a P/E ratio of -1.33 and a beta of 1.73. Myriad Genetics, Inc. has a fifty-two week low of $3.53 and a fifty-two week high of $8.59. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.19 and a current ratio of 2.40.

Myriad Genetics (NASDAQ:MYGN – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). The company had revenue of $200.40 million during the quarter, compared to analysts’ expectations of $202.42 million. Myriad Genetics had a negative return on equity of 8.51% and a negative net margin of 48.24%.The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.03) EPS. Research analysts predict that Myriad Genetics, Inc. will post -0.17 earnings per share for the current year.

Myriad Genetics Company Profile

(Free Report)

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.